Publication details
Lipertance® - dva problémy, jedno řešení
| Title in English | Lipertance® - two problems, one solution |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue - Interní medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | hypertension; dyslipidaemia; fixed combinations |
| Description | Hypertension and dyslipidaemia are the most important risk factors of cardiovascular diseases, which very frequently appear together. About 70% of hypertensive patients suffer from dyslipidaemia. The first line treatment of hypertension are ACE inhibitors and dihydropyridines and the first line treatment for dyslipidaemia are statins. The combination of perindopril + amlodipine was more effective in the treatment cardiovascular events in hypertensive patients than a combination of a beta blocker + diuretic in the ASCOT study, and adding of atorvastatin potentiated this effect. This is a clear evidence of positive effect of the combination atorvastatin + perindopril + amlodipine in the primary prevention. In the EUROPA study, perindopril showed a decrease of cardiovascular events if compared with placebo in patients with ischaemic heart disease, and adding of amlodipine increased this effect. The statin treatment decreases cardiovascular mortality in patients with ischaemic heart disease irrespectively of the cholesterol level. This is clear evidence for the positive effect of the combination atorvastatin + perindopril + amlodipine in secondary prevention. The positive effect of fixed combinations as compared with monotherapies of the same components was repeatedly confirmed especially in studies investigating hypertension. The fixed triple combination of atorvastatin + perindopril arginine + amlodipine increases the adherence of patients to the treatment and this enables a more effective control of both risk factors – hypertension and dyslipidaemia in primary as well as secondary prevention. |